James K Chow, Akshay Bagai, Mary K Tan, Bryan J Har, Amelia M C Yip, Mario Paniagua, Basem Elbarouni, Kevin R Bainey, Jean-Michel Paradis, Robert Maranda, Warren J Cantor, Mark J Eisenberg, Jean-Pierre Dery, Mina Madan, Tomas Cieza, Alexis Matteau, Sherryn Roth, Shahar Lavi, Anthony Glanz, Dongsheng Gao, Ravi Tahiliani, Robert C Welsh, Hahn Hoe Kim, Simon D Robinson, Benoit Daneault, Aun-Yeong Chong, Michel R Le May, Vineeta Ahooja, Jean C Gregoire, Pierre-Louis Nadeau, Zachary Laksman, Brett Heilbron, Derek Yung, Kunal Minhas, Ronald Bourgeois, Christopher B Overgaard, Hamid Bonakdar, Giridhar Logsetty, Andrea J Lavoie, Robert De LaRochelliere, Samer Mansour, Caroline Spindler, Andrew T Yan, Shaun G Goodman
BACKGROUND: Selecting the appropriate antithrombotic regimen for patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) or have had medically managed acute coronary syndrome (ACS) remains complex. This multi-centre observational study evaluated patterns of antithrombotic therapies utilized among Canadian patients with AF post-PCI or ACS. METHODS AND RESULTS: By retrospective chart audit, 611 non-valvular AF patients [median (interquartile range) age 76 (69-83) years, CHADS2 score 2 (1-3)] who underwent PCI or had medically managed ACS between August 2018 and December 2020 were identified by 68 cardiologists across eight provinces in Canada...
March 15, 2023: Journal of Cardiology